Aclaris Therapeutics (ACRS) Preferred Stock Liabilities (2014 - 2015)
Aclaris Therapeutics (ACRS) recorded quarterly Preferred Stock Liabilities of $78.3 million in Q3 2015, up 113.5% quarter-over-quarter from $36.7 million in Q4 2014.
Aclaris Therapeutics (ACRS) Preferred Stock Liabilities (2014 - 2015) Analysis & Trends
Aclaris Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $78.3 million for Q3 2015.
- In Q3 2015, Preferred Stock Liabilities changed N/A year-over-year to $78.3 million; the TTM figure through Sep 2015 stood at $78.3 million (changed N/A YoY), while the FY2014 annual figure was $36.7 million, up 59.47% from the prior year.
- Preferred Stock Liabilities was $78.3 million for Q3 2015 at Aclaris Therapeutics, up from $36.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $78.3 million in Q3 2015 to a low of $36.7 million in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 78.31 Mn |
| Dec 31, 2014 | 36.68 Mn |